CD274 and triple-negative breast carcinoma: Immunocheckpoint inhibitor: PD-1/PD-L1 inhibitor combined with anti-inflammatory treatment can reverse the immunosuppressive microenvironment and show efficacy in triple negative breast cancer (36).